Exelixis | EXEL - Ebitda


Exelixis reported $248.93M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -125.8M 20.45M Jun/2025
Amgen USD 5.91B 2.31B Sep/2025
AstraZeneca USD 4.96B 127M Jun/2025
Bayer EUR 1.51B 1.28B Sep/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Cytokinetics USD -107.82M 45.51M Jun/2025
Eisai JPY 23.48B 14.68B Sep/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Exelixis USD 248.93M 28.02M Sep/2025
Genmab DKK 477M 101M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Incyte USD 581.52M 358.87M Jun/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Moderna USD -208M 552M Sep/2025
Neurocrine Biosciences USD 246.7M 93.8M Sep/2025
Novartis USD 5.88B 290M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Sanofi EUR 5.66B 3.77B Sep/2025
Takeda JPY 448.13B 173.98B Dec/2025
Ultragenyx Pharmaceutical USD -91.34M 35.09M Jun/2025
Xencor USD -30.52M 6.39M Jun/2025